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Abstract 1 
Background: Human prostate cancers display numerous DNA methylation changes 2 
compared to normal tissue samples. However, definitive identification of features related 3 
to the cellsÕ malignant status has been compromised by the predominance of cells with 4 
luminal features in prostate cancers. 5 
Methods: We generated genome-wide DNA methylation profiles of cell subpopulations 6 
with basal or luminal features isolated from matched prostate cancer and normal tissue 7 
samples.  8 
Results: Many frequent DNA methylation changes previously attributed to prostate 9 
cancers are here identified as differences between luminal and basal cells in both normal 10 
and cancer samples. We also identified changes unique to each of the two cancer 11 
subpopulations. Those specific to cancer luminal cells were associated with regulation of 12 
metabolic processes, cell proliferation and epithelial development. Within the prostate 13 
cancer TCGA dataset, these changes were able to distinguish not only cancers from 14 
normal samples, but also organ-confined cancers from those with extra-prostatic 15 
extensions. Using changes present in both basal and luminal cancer cells, we derived a 16 
new 17-CpG prostate cancer signature with high predictive power in the TCGA dataset. 17 
Conclusions: This study demonstrates the importance of comparing phenotypically 18 
matched prostate cell populations from normal and cancer tissues to unmask biologically 19 
and clinically relevant DNA methylation changes. 20 
 21 
  22 
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Background 23 
Treatment-nave prostate cancer (PCa) is characterized by an abnormal accumulation of 24 
proliferative cells with a molecular phenotype similar to the luminal cells present in the 25 
normal prostate1,2. However, PCa samples also contain a small population of tumour cells 26 
with basal features. These cells possess Òcancer stem cellÓ features, appear to be 27 
treatment-resistant, and are proposed to serve as a reservoir for tumour recurrence after 28 
castration therapy3-6. DNA methylation of bulk PCa samples has been well studied7 and 29 
aberrant methylation of promoter regions found to be a consistent feature8, albeit with 30 
high variability both between patients and within single tumours9. Their frequency and 31 
presence in pre-malignant tissues support a strong selective pressure for DNA 32 
methylation changes during cancer development7. However, DNA methylation is 33 
dynamically regulated during tissue development and cell differentiation10, and distinct 34 
cell types possess specific DNA methylation profiles within the same tissue11-13. 35 
Therefore, the luminal molecular features of bulk PCa samples, in contrast to the almost 36 
equal proportion of basal and luminal cells in normal prostate tissues, complicate the 37 
interpretation of datasets generated on whole tissue extracts, where changes associated to 38 
differences in cell types may mask the presence of malignancy-associated signatures. 39 
Recent developments in tissue processing and the identification of surface 40 
markers suitable for the prospective isolation of viable basal and luminal cells from 41 
normal prostate tissues have enabled studies of their molecular and biological 42 
characteristics14-17. Use of this approach has revealed that many of the genes 43 
downregulated in normal luminal cells compared to basal cells are frequently 44 
hypermethylated in PCa18. This data implies a functional link between DNA 45 
!3 
hypermethylation and the observed expansion of cells with a luminal phenotype in PCa. 46 
However, very little is known about the specific DNA methylation features of PCa cells 47 
with basal and luminal phenotypes in comparison to their normal counterparts. To 48 
address this issue, we generated genome-wide DNA methylation profiles of FACS-49 
purified populations of cells with basal and luminal features from a series of freshly 50 
isolated patient-matched tumour and normal samples from individuals undergoing radical 51 
prostatectomy. Our results show that many DNA methylation changes frequently seen in 52 
PCa are characteristic differences between luminal and basal cells from both normal and 53 
cancer samples. From these datasets, we were also able to identify two sets of tumour-54 
specific changes of potential clinical interest. One set consists of changes that are specific 55 
to PCa luminal cells; the other set are changes shared by both basal and luminal tumour 56 
but not normal prostate cells.  57 
 58 
  59 
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Methods 60 
Tissue processing:  61 
Prostate tissues were obtained from patients undergoing radical prostatectomy at Castle 62 
Hill Hospital (Cottingham, UK) with informed patient consent and approval from the 63 
NRES Committee Yorkshire & The Humber (LREC Number 07/H1304/121). Tissues 64 
were sampled immediately after surgery. For radical prostatectomies, three core needle 65 
biopsies were taken from four different sites (left base, left apex, right base, right apex) 66 
and were directed by previous pathology, imaging and palpation. Tissues were 67 
transported in RPMI-1640 with 5% FCS and 100U/ml antibiotic/antimitotic solution at 68 
4¼C, and processed immediately upon arrival. PCa diagnosis was confirmed by 69 
histological examination of the whole prostate. Tissues were disaggregated as previously 70 
described19, and all reagents were supplemented with 10 nM R1881 to better preserve the 71 
viability of luminal cells.  72 
 73 
Fluorescence activated cell sorting (FACS) and characterization of cell populations: 74 
Single-cell suspensions were labelled with Lineage Cell Depletion Kit (human) and 75 
CD31 MicroBead Kit (Miltenyi Biotec) and Lin+/CD31+ cells depleted twice using 76 
MACS LS Columns (Miltenyi Biotec). Lin-/CD31- cells were then labelled with EpCAM-77 
APC, CD49f-FITC and CD24-PE (Miltenyi Biotec) and DAPI and 78 
EpCAM+/CD49f+/CD24- and EpCAM+/CD49f-/CD24+ sorted at >95% purity using a 79 
MoFlo (Beckman Coulter) cell sorter. Sorted populations were characterized by 80 
immunofluorescence and qRT-PCR as previously described18. 81 
 82 
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Reduced Representation Bisulphite Sequencing (RRBS): 83 
DNA was extracted from FACS-sorted populations using phenol/chloroform extraction 84 
and ethanol precipitation. DNA was quantified using a NanoDrop 1000 85 
Spectrophotometer (Thermo Fisher Scientific), and shipped to Zymo Research for RRBS 86 
analysis. Bisulphite conversion, library preparation, sequencing, and initial 87 
bioinformatics analyses were performed by Zymo Research following the Methyl-88 
MiniSeq pipeline. 89 
 90 
Sequence data processing and methylation calls: 91 
Fastq files were trimmed using Trim Galore! v0.4.1 92 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with the following 93 
parameters: --fastqc --illumina --paired --rrbs --non_directional. Trimmed sequences were 94 
aligned to the human genome (hg19 downloaded from UCSC, 08-Mar-2009 version) 95 
using bsmap v2.9020 and the following parameters: -m 0 -x 1000 -n 1 -p 8 -S 1. The 96 
resulting bam files were sorted and indexed using samtools v0.1.1921, and methylation 97 
and coverage calls for each CpG site calculated using the methratio.py script in the bsmap 98 
software (Supplementary Table 1). Methylation calls were then filtered for low (<3) and 99 
high (>99.95%) read coverage and merged in non-overlapping genomic bins of 100 bp 100 
using the methylKit package v0.99.222 within R v3.3.1 to increase comparability between 101 
samples. All subsequent analyses were carried out using only those genomic bins covered 102 
in all samples, with the exception of the results presented in Supplementary Fig. 2  and 103 
Supplementary Table 3 which were generated using single GpG information. 104 
 105 
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Identification of differentially methylated regions (DMRs): 106 
DMRs were calculated using methylKit22; with all pairwise comparisons between the four 107 
cell populations carried out and similar populations from different donors defined as 108 
biological replicates. The patient of origin was used as a categorical covariate to account 109 
for the strong inter-donor variability seen. All p-values were generated using a logistic 110 
regression model and corrected for multiple testing using the SLIM method23. DMRs 111 
were defined as those genomic bins with q-values <0.05 and absolute methylation 112 
difference >10% in each pairwise comparison. 113 
 114 
Characterization of DMRs: 115 
All genomic features were downloaded from the UCSC Table browser 116 
(genome.ucsc.edu) for the hg19 genome. Gene models: ÒrefGeneÓ (RefSeq Genes), CpG 117 
Islands: ÒcpgIslandExtÓ, Evolutionary conservation: ÒphastCons100wayÓ, DNase 118 
hypersensitivity sites (DHSs): ÒwgEncodeRegDnaseClusteredV3Ó, transcription factor 119 
binding sites (TFBSs): ÒwgEncodeRegTfbsClusteredV3Ó, repeats: ÒrmskÓ 120 
(RepeatMasker). Overlaps and distances of DMRs to other genomic features were 121 
calculated using BEDtools v2.26.024, and significance of enrichments or depletions was 122 
calculated using custom R scripts. All p-values <10-300 were approximated to 10-300 to 123 
avoid reaching the minimum value for a floating-point number (2.2*10-308). Average 124 
conservation signals around DMRs were calculated using bwtool v1.025. P-values were 125 
calculated using a bootstrapping approach comparing the average conservation of the 126 
distal DMRs with the average of an equal number of randomly selected, non-overlapping, 127 
distal genomic bins, 1000 times. Gene ontology (GO) analysis was performed using 128 
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GREAT v3.026, using all covered genomic bins as background and the default ÒBasal plus 129 
extensionÓ association rules. Results were filtered to include only GO categories, with a!130 
BenjaminiÐHochberg corrected (FDR) hypergeometric test p-value <0.05 and ≥3 genes 131 
with associated regions. K-means clustering of GO categories (biological processes only) 132 
was based on information similarity values calculated using the GOSim package within R 133 
v3.3.1. Promoters frequently altered in PCa were downloaded from the review by Massie 134 
et al., 20177. Only promoters reported by ≥3 studies were considered frequently altered. 135 
Genome browser plots were generated using the package Sushi within R v3.3.1 and 136 
custom scripts. 137 
 138 
TCGA data analysis: 139 
Illumina Infinium HumanMethylation450 data generated within the The Cancer Genome 140 
Atlas (TCGA) consortium27 was downloaded (pre-processed Level 3 data only) from the 141 
NCI Genomic Data Commons website using the provided GDC Data Transfer Tool (data 142 
downloaded on 7th Dec 2016). Clinical data was downloaded from firebrowse.org (8th 143 
Dec 2016). The presence of evident batch effects was excluded by visualizing the data on TCGA 144 
Batch Effects (http://bioinformatics.mdanderson.org/tcgambatch/). A data matrix containing 145 
the beta values for each sample was generated using custom scripts. Probes were mapped 146 
to hg19 using the positions officially reported by Illumina. Overlap of array probes with 147 
DMRs was carried out using BEDtools v2.26.0. Hierarchical clustering was based on 148 
Euclidean distances of unscaled beta-values. Logistic model training using least absolute 149 
shrinkage and selection operator (LASSO) regression was performed using the glmnet 150 
package within R v3.3.1 on a random selection of 70% of the samples. 200 lambda values 151 
!8 
ranging from e-7 to e-2 were tested and 10-fold cross validation performed. The lambda 152 
with the minimum mean cross-validated error was selected and resulted in 17 probes with 153 
non-zero coefficients. The optimal model was then tested on the remaining 30% of 154 
samples and receiver operator curve and area under the curve (AUC) calculated using the 155 
ROCR package. 156 
 157 
  158 
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Results 159 
Phenotypically defined prostate cells from patient-matched normal and PCa 160 
samples show donor-specific DNA methylation profiles 161 
Matched tumour-directed (cancer) and contralateral (normal) core needle biopsies (1 or 2 162 
per site) were obtained from 4 treatment-nave prostate cancer patients undergoing radical 163 
prostatectomies. These samples were then enzymatically dissociated and labeled with 164 
antibodies against EpCAM, CD49f and CD24 to enable the prospective isolation of 165 
luminal (EpCAM+CD49f-CD24+) and basal (EpCAM+CD49f+CD24-) cells at >95% 166 
purity (Fig. 1A). EpCAM+CD49f+CD24- cells expressed higher levels of molecular 167 
markers associated with basal cells and lower levels of luminal markers compared to 168 
EpCAM+CD49f-CD24+ cells from the same biopsy, both at the mRNA and protein level 169 
(Supplementary Fig. 1A-B). For convenience, we named the paired subsets as follows: 170 
Cancer Luminal (CL) EpCAM+CD49f-CD24+ cells purified from tumour-directed 171 
biopsies; Cancer Basal (CB) EpCAM+CD49f+CD24- cells purified from tumour-directed 172 
biopsies; Normal Luminal (NL) EpCAM+CD49f-CD24+ cells from contralateral 173 
biopsies; Normal Basal (NB) EpCAM+CD49f+CD24- cells purified from contralateral 174 
biopsies. This yielded 4 CL and CB populations, and 3 matched NL and NB populations, 175 
as in one prostate the palpable tumour was extended to most of the prostate and it was not 176 
possible to obtain a contralateral ÒnormalÓ tissue biopsy (Supplementary Fig. 1C). DNA 177 
obtained from each of these isolates was then subjected to Reduced Representation 178 
Bisulphite Sequencing (RRBS). On average, this generated information on the DNA 179 
methylation status of >8.9x106 cytosines within CpG sites per sample (range 8x106 Ð 180 
9.6x106, with an average coverage of 7.5 reads, Supplementary Table 1). The data was 181 
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processed as described in Methods, and binned into 100 bp genomic regions to maximize 182 
the comparability between samples (932,905 bins covering 4.1x106 CpGs in all samples). 183 
Unsupervised hierarchical clustering of the top 1% most variable regions (bins) across all 184 
samples showed clustering primarily according to the patient of origin, rather than the 185 
subset analyzed (Fig. 1B). This indicates a high donor-determined variation in CpG 186 
methylation, consistent with previous reports of similarly accrued data28. 187 
 188 
Distinct DNA methylation profiles in basal and luminal cells 189 
We then calculated DMRs for all pairwise comparisons between the 4 sorted populations 190 
(Fig. 1C, Supplementary Table 2). Among these, the comparison between CB and NB 191 
cells (CB-NB comparison) produced the smallest number of DMRs. In contrast, a large 192 
number of DMRs were seen when either normal or cancer luminal cells were compared 193 
with either source of basal cells (i.e., NL-NB, NL-CB, CL-NB and CL-CB, Fig. 1D).  Of 194 
the DMRs revealed in these latter comparisons, ~2/3 were hypermethylated in luminal 195 
cells, which correlates with the higher levels of DNMT3a seen in these cells18. We also 196 
calculated differential methylation on single CpGs (prior the 100bp binning) with very 197 
similar results (Supplementary Fig. 2  and Supplementary Table 3). Moreover, integration 198 
of the DMRs identified in NL-NB proximal (±5 kb) to annotated transcriptional start sites 199 
(TSSs) with RNA-seq data of similarly purified cells15 showed the expected inverse 200 
correlation (Supplementary Fig. 3A).  201 
We also found an extensive overlap in the DMRs obtained from both the NL-NB and NL-202 
CB comparisons, and also from the CL-NB and CL-CB comparisons (Supplementary Fig. 203 
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3B-C). Accordingly, we focussed our subsequent analyses on comparisons of NL-NB and 204 
CL-CB, where cells from the same biopsy could be compared directly.   205 
Characterization of the genomic features of the DMRs thus identified showed that 206 
>50% of them fell outside of CpG islands, shores or shelves (Fig. 1E), and >70% were >5 207 
kb away from any annotated TSSs (Fig. 1F-G). These features were particularly 208 
pronounced (highly significant hypergeometric test) for the hypomethylated DMRs 209 
identified in the comparisons of NL-NB, CL-CB and CL-NL. Because hypermethylated 210 
and hypomethylated DMRs might be anticipated to differ in their genomic context, their 211 
impact on the biological properties of basal and luminal cells could also be different. 212 
 213 
Distal hypermethylated DMRs are enriched in enhancer features 214 
Given that most of the DMRs identified were outside CpG islands and far from TSSs, we 215 
asked whether they might affect distal regulatory elements (enhancers). We therefore 216 
examined three genomic characteristics of such elements: evolutionary conservation29, 217 
open chromatin shown by hypersensitivity to DNase I30, and presence of TFBSs31. Distal 218 
hypermethylated DMRs in each comparison were enriched for evolutionarily conserved 219 
sequences (Fig. 2A, bootstrapped p-value) and overlapped significantly with both DHSs 220 
and ChIP-seq-defined TFBSs (identified within the ENCODE project, Fig. 2B-C, 221 
hypergeometric test).  Distal hypomethylated DMRs generally scored lower than the 222 
hypermethylated counterparts for each metric measured. DMRs hypomethylated in the 223 
CL-CB and CL-NL comparisons showed the weakest enrichments. However, all distal 224 
hypomethylated DMRs had high overlaps with genomic repetitive elements (Fig. 2D). 225 
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Specifically, LINE and LTR elements, but not SINE elements, were significantly 226 
enriched in the distal CL hypomethylated regions. 227 
GO enrichment analysis (Fig. 2E, Supplementary Fig. 4) showed that 228 
hypermethylated DMRs in NL-NB were enriched for more than 500 terms, many of 229 
which were linked to prostate development or epithelial stem cell regulation; while 230 
hypomethylated DMRs in the same comparison were enriched for terms related to 231 
androgen receptor signalling and response to cytokines. In the CL-CB comparison, 232 
hypermethylated DMRs were also enriched for more than 500 terms, 311 of which were 233 
also identified in the NL-NB comparison, suggesting a high functional overlap in 234 
hypermethylated regions in luminal cells from both normal and cancer samples. In the 235 
CL-NL comparison, hypermethylated DMRs were enriched in terms related to cell 236 
adhesion, while hypomethylated DMRs were enriched in terms related to epithelial 237 
morphogenesis. These results indicate that several pathways fundamental to the 238 
establishment and maintenance of the normal prostate epithelium are altered in cancer 239 
cells with a luminal phenotype.  240 
 241 
Phenotype-specific DMRs are shared in normal and cancerous prostate tissues 242 
As suggested by the enriched GO analyses, we found a 28% overlap in all the DMRs 243 
identified from the NL-NB and the CL-CB comparisons (3852/13816, Fisher's exact test 244 
p−value < 10-300, Fig. 3A). Hierarchical clustering of all samples based on both sets of 245 
DMRs separated them by phenotype (Fig. 3B), reinforcing the presence of a strong 246 
phenotypic signature independent of disease state. These shared DMRs were enriched in 247 
features characteristic of enhancers (Supplementary Fig. 5A-D) and linked to GO terms 248 
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related to prostate development, regulation of epithelial stem cells and androgen receptor 249 
signalling (Supplementary Fig. 5E-F). Moreover, hypermethylated DMRs were highly 250 
enriched for TFBSs of TP63, TP53 and NF1, and hypomethylated DMRs for FOXA1, 251 
p65-NFkB and GATA3 (Fig. 3C), all well-known regulators of basal and luminal 252 
epithelial cells, respectively. Interestingly, 26 of the 168 genes described as frequently 253 
differentially methylated in PCa7, showed hyper- or hypomethylated DMRs within 5 kb 254 
of their TSSs in both the NL-NB and CL-CB comparisons (Fig. 3D). These included the 255 
frequently hypermethylated genes, GSTP1 and CCDC8 (Fig. 3E-F).  256 
In summary, these analyses identified a large set of phenotype-specific and 257 
disease-independent DMRs, both of which contained many binding sites for TFs with 258 
known regulatory roles in the normal prostate.  259 
 260 
CL hypermethylate PRC2 target sites and hypomethylate repetitive elements 261 
A second group of genes frequently hypermethylated in PCa were found hypermethylated 262 
in both the CL-CB and CL-NL comparisons (Fig. 4a), but not in the NL-NB comparison. 263 
These might be expected to reflect a PCa-specific methylation signature. DMRs 264 
identified in the CL-CB and CL-NL comparisons showed that many were shared (1472 265 
DMRs, Fisher's exact test p−value < 10-300, Fig. 4B) with very few also different between 266 
NL and NB cells (106 DMRs). 65% of these CL-specific hypermethylated DMRs were 267 
distal to TSSs and were again highly enriched for enhancer features, but significantly 268 
depleted in repetitive elements (Supplementary Fig. 6A-E). These regions were 269 
associated with GO terms related to metabolic processes, cell proliferation and epithelial 270 
development (Fig. 4C) and showed a high enrichment of DNA sequences potentially 271 
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bound by EZH2 and SUZ12, two main members of the PRC2 complex (Supplementary 272 
Fig. 6F). On the other hand, distal hypomethylated DMRs were not enriched for any 273 
feature of putative regulatory regions, but significantly overlapped with LINE and LTR 274 
elements. 275 
Since the CL subset represents the majority of the cells in untreated PCa samples, 276 
we hypothesized that aberrant methylation of these DMRs would be measurable even 277 
when whole tissue homogenates are analysed. We therefore interrogated the DNA 278 
methylation array dataset for PCa made available by the TCGA consortium, which 279 
consists of 50 PCa samples with matched normal counterparts, 452 additional PCa 280 
samples without normal counterparts, and 1 metastatic PCa sample27. 255 array probes 281 
overlap these 1472 DMRs. Hierarchical clustering of the 50 matched normal and PCa 282 
samples showed an almost perfect subdivision based on the malignancy status of the 283 
samples (TPR = 0.92, TNR = 0.92, Chi-squared test p-value = 2.4x10-16, Fig. 4D). The 284 
same analysis carried out on all 553 samples produced similar results, with one cluster 285 
highly enriched in normal samples (Chi-squared test p-value = 1.7x10-39, Supplementary 286 
Fig. 6G).  This clustering also appeared to divide the PCa samples into two main groups, 287 
according to their differences from the normal samples. Exclusive analysis of the cancer 288 
samples confirmed this clustering pattern (Fig. 4E) and showed one cluster to be 289 
significantly enriched for samples with extra-prostatic extensions (pT3 or pT4 in TNM 290 
classification, Chi-squared test p-value < 0.005) in the absence of significant differences 291 
in Gleason score (Chi-squared test p-value >0.1).  292 
Overall, these results indicate that phenotypic luminal PCa cells possess an 293 
aberrant methylation signature characterized by hypermethylation of putative regulatory 294 
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sequences involved in tissue development, and hypomethylation of LINEs and LTRs 295 
repetitive elements. This signature was also able to distinguish cancer samples from 296 
normal, and organ-confined from extraprostatic disease.  297 
 298 
Identification of PCa-specific, phenotype-independent DMRs 299 
Comparisons of the DMRs in the CL-NL and CB-NB pairs showed a small but 300 
significant overlap of both hyper- and hypomethylated DMRs in each (189 DMRs in 301 
total, Fig. 5A). These common DMRs were able to cluster all samples according to their 302 
disease state in a phenotype-independent manner (Supplementary Fig. 7A). Notably, they 303 
included DMRs close to many genes previously implicated in prostate cancer (e.g., 304 
NEAT1, MTOR, RHCG, KCNC2, WT1, HOXC12, KMT2B, Fig. 5B). To determine 305 
whether these DMRs would be altered in an independent dataset, we applied the same 306 
analysis to the TCGA dataset, where 66 array probes overlapped these 189 DMRs. 307 
Hierarchical clustering of the 50 matched normal and PCa samples produced a single 308 
cluster containing 46/50 normal samples and 10/50 PCa samples (TPR = 0.8, TNR = 309 
0.92, Chi-squared test p-value = 1.8x10-12, Fig. 5C). Application of the same analysis to 310 
all samples in the TCGA database produced similar results: one cluster was highly 311 
enriched in normal samples (TPR = 0.87, TNR = 0.74, Chi-squared test p-value = 8.3x10-312 
26, Supplementary Fig. 7B), indicating that at least some of these DMRs are frequently 313 
altered in PCa.  314 
To select the probes most strongly associated with disease state (i.e., PCa vs 315 
normal), we trained a logistic model using LASSO regression on 70% of the TCGA 316 
samples and selected a 17-probe signature (Fig. 5D). We then tested this model on the 317 
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remaining 30% of the dataset. This resulted in an AUC of 0.92 (TPR = 0.9, TNR = 0.94, 318 
Fisher's exact test p−value = 2.82x10-12 at the selected cut-off of 0.8, Fig. 5E-F, 319 
Supplementary Table 4). The 17-probe signature also included sequences proximal to 320 
several genes with recognized importance in PCa (e.g., PLAGL1/HYMAI, HOXC12, 321 
KCNC2), but was completely non-overlapping with other similar signatures recently 322 
developed for PCa32-36. 323 
 324 
Discussion 325 
PCa is characterized by frequent aberrant DNA methylation of many genomic sites that 326 
may contain clinically relevant signatures7,37. The early establishment (presence in pre-327 
neoplastic tissues) and high prevalence of these aberrant patterns is also suggestive of 328 
their direct involvement in PCA tumorigenesis. However, the normal prostate epithelium 329 
is composed of similar numbers of luminal and basal cells, whereas most treatment-nave 330 
prostate cancers are largely composed of cells with many luminal features. This shift in 331 
favor of a transcriptional and epigenomic program of normal luminal cells might mask or 332 
complicate the identification of cancer-specific features in prostate cancer when bulk 333 
analyses are performed on this type of tumour.  334 
We now report a detailed comparison of genome wide methylation profiles 335 
obtained separately from epithelial cells with luminal and basal phenotypes, isolated with 336 
a high purity from patient-matched normal and cancer biopsy samples. From comparative 337 
analyses of these profiles, we found a major proportion of the methylation differences 338 
between normal basal and luminal cells were conserved in their malignant counterparts. 339 
These affected many promoters frequently described as aberrantly methylated in bulk 340 
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PCa compared to normal tissues, consistent with the increased representation of cells with 341 
a luminal phenotype in PCa, in which a higher proportion of cells carrying a methylation 342 
signature of normal luminal cells might then be expected.  343 
However, our study made it possible to identify, for the first time, regions 344 
specifically altered in the luminal fraction of PCa. The hypermethylated DMRs in this 345 
group were genes associated to genes involved in metabolic processes, cell proliferation 346 
and epithelial development, all functions clearly deregulated in prostate cancer, therefore 347 
potentally containing major cancer driver events. Furthermore,  hypomethylated DMRs 348 
were highly enriched in repetitive elements, a feature also previously reported in many 349 
cancer types, where they have been thought to contribute to genomic instability and 350 
aberrant gene expression38-40. 351 
Importantly, this set of DMRs was able to discriminate not only normal and PCa 352 
samples in the TCGA dataset, but also PCa samples with or without extra-prostatic 353 
extensions, the former being indicative of highly aggressive, invasive cancers. Since this 354 
distinction was not evident from the Gleason grades of these tumours, the epigenetic data 355 
may reflect a an acquisition of specific aberrant epigenomic changes that herald disease 356 
progression7,41-43. Genomic regions consistently altered in both tumour phenotypes in the 357 
PCa samples analyzed also have potential clinical importance. Indeed, the new logistic 358 
model constructed from these regions makes use of only 17 probes to distinguish normal 359 
and PCa samples with similar specificity and sensitivity to previously developed, non-360 
overlapping models35,36, and may be useful in the context of the low mutagenic burdens 361 
seen in most hormone-nave prostate cancers.  362 
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The results reported here show that many DNA methylation changes commonly 363 
associated with PCa cells are explained by a predominant luminal phenotype of the 364 
treatment-nave PCa population, and are not cancer-specific nor are likely to contain 365 
driver events. Importantly however, we were able to identify two separate classes of PCa-366 
specific DNA methylation changes: those specific to cancer luminal cells that can 367 
distinguish both normal from cancer samples and organ-confined cancers from those with 368 
extra-prostatic extensions; those changes common to basal and luminal cancer cells that 369 
are able to distinguish PCa efficiently from normal samples. These two novel sets of 370 
cancer-specific changes clearly demonstrate the potential of profiling normal and cancer 371 
cell subpopulations in identifying signatures that may contain previously unrecognized 372 
driver events in the development and progression of PCa. 373 
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 536 
Figure Legends 537 
Fig. 1: Identification of DMRs between prostate cancer cell populations. (A) 538 
Representative FACS profiles of a͒cell suspension prepared from core needle biopsies of 539 
a radical prostatectomy sample. (B) Heatmap showing scaled methylation values of the 540 
top 1% most variable regions (100 bp bins) in the samples analyzed. Hierarchical 541 
clustering is based on Euclidean distance of the unscaled values and complete linkage. 542 
(C) Diagram showing all pairwise comparisons carried out. (D) Number of DMRs found 543 
in each comparison. (E) Overlap of DMRs with CpG islands, shores (2 kb flanking 544 
islands) or shelves (2 kb flanking shores). P-values from hypergeometric test against all 545 
regions. E = enriched, D = depleted. (F) Distribution of distances of DMRs to the closest 546 
TSS. Grey box indicates ±5 kb from a TSS. Purple lines: hypermethylated DMRs, orange 547 
!24 
lines: hypomethylated DMRs, gray line: all regions. (G) Proportion of DMRs proximal or 548 
distal to TSSs. P-values from hypergeometric test against all regions. E = enriched, D = 549 
depleted. 550 
 551 
Fig. 2: Hypermethylated distal DMRs have features of enhancers. (A) Average plots 552 
of evolutionary conservation scores of the distal DMRs in each set. Purple lines: 553 
hypermethylated DMRs; orange lines: hypomethylated DMRs, gray line: all regions. P-554 
values are from bootstrapping analysis. (B) Proportion of distal DMRs overlapping with 555 
DHSs (identified by ENCODE). P-values from hypergeometric test against all regions. E 556 
= enriched, D = depleted. (C) Overlap of distal DMRs with ChIP-seq derived TFBSs 557 
(identified by ENCODE). P-values are from hypergeometric tests against all regions. E = 558 
enriched, D = depleted. (D) Overlap of each set of distal DMRs with repetitive elements 559 
(UCSC repeatMask), SINEs, LINEs and LTRs. P-values from hypergeometric tests 560 
against all regions. E = enriched, D = depleted. (E) Number of GO terms enriched by 561 
each set of DMRs. GO terms identified using GREAT (FDR<0.05 and at least 3 genes in 562 
the set). 563 
 564 
Fig. 3: Shared phenotype-specific DMRs. (A) Overlap between the DMRs identified in 565 
the NL-NB and CL-CB comparisons. P-values derived from Fisher's exact test. (B) 566 
Heatmap showing scaled methylation values of the DMRs identified in the NL-NB (left) 567 
or CL-CB (right) comparisons. Hierarchical clustering is based on Euclidean distances of 568 
the unscaled values and complete linkage. (C) TFBSs enriched in the hypermethylated 569 
(purple) or hypomethylated (orange) DMRs common between the NL-NB and CL-CB 570 
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comparisons. Left panel: analysis performed using HOMER findMotifs, p-values from 571 
binomial test. Right panel: enrichment of ENCODE defined TFBSs, p-values from 572 
hypergeometric test against all regions. (D) Frequently hyper- or hypomethylated genes 573 
in PCa7 that were also hypermethylated (purple) or hypomethylated (orange) in the NL-574 
NB and CL-CB comparisons. (E-F) Genome browser plots of the promoter regions of 575 
GSTP1 (E) and CCDC8 (F). Grey squares are the bins analyzed. Lines and shaded areas 576 
represent mean ±SEM of each category (NB=light blue, NL=light red, CB=dark blue, 577 
CL=dark red). DMRs are shown on top: hypermethylated=purple, 578 
hypomethylated=orange. 579 
 580 
Fig. 4: Aberrant methylation in CL. (A) Frequently hyper- or hypomethylated genes in 581 
PCa7 that are also hypermethylated (purple) or hypomethylated (orange) in the CL-CB 582 
and CL-NL comparisons. (B) Overlap between the DMRs identified in the CL-CB and 583 
CL-NL comparisons. P-values derived from Fisher's exact test.  (C) Clustering of the 584 
gene ontologies (biological process) enriched in DMRs common between the CL-CB and 585 
CL-NL comparisons based on information similarity. Each circle shows an individual GO 586 
term enriched in regions hypermethylated (purple), hypomethylated (orange) or both 587 
(green), the size of the circles is proportional to the enrichment p-value. The 2 main 588 
clusters of GO terms determined by k-means are highlighted (light blue and pink), and 589 
named after the most frequent terms. (D) Heatmap showing scaled methylation values (b-590 
values) of probes overlapping the DMRs common to the CL-CB and CL-NL comparisons 591 
in the PCa samples (magenta)  and matched normal samples (green) within the TCGA 592 
dataset. Hierarchical clustering based on Euclidean distances of the unscaled values and 593 
!26 
complete linkage. The dark green and gray clusters were generated by cutting the tree at 594 
the first bifurcation. (E) Heatmap showing scaled methylation values (b-values) of probes 595 
overlapping the DMRs common to the CL-CB and CL-NL comparisons in the PCa 596 
samples (matched normal samples not included) of the TCGA dataset. Hierarchical 597 
clustering based on Euclidean distance of the unscaled values and complete linkage. The 598 
dark green and gray clusters are generated by cutting the tree at the first bifurcation. 599 
 600 
Fig. 5: PCa-specific DMRs shared between CB and CL. (A) Overlap between the 601 
DMRs identified in the CL-NL and CB-NB comparisons. P-values derived from Fisher's 602 
exact test.  (B) Genome browser views of KCNC2 promoter (top) and RHCG exon 2 603 
(bottom). Grey squares are the bins analyzed. Lines and shaded areas represent mean 604 
±SEM of each category (NB=light blue, NL=light red, CB=dark blue, CL=dark red). 605 
DMRs are shown on top: hypermethylated=purple, hypomethylated=orange. (C) 606 
Heatmap showing scaled methylation values of probes overlapping the DMRs common 607 
between CL-CB and CB-NB in the matched normal and cancer samples within the TCGA 608 
dataset. Hierarchical clustering based on Euclidean distances of the unscaled values and 609 
complete linkage. The dark green and gray clusters were generated by cutting the tree at 610 
the first 2 bifurcations. (D) Selection of a 17-probe signature distinguishing normal and 611 
PCa samples applying LASSO regression on a logistic model of the training dataset (70% 612 
of the TCGA samples). Lines show the changes in coefficients in relation to different 613 
lambdas. The vertical dashed line shows the optimal lambda identified using cross-614 
validation. (E) Receiver-operating characteristic curve generated by applying the optimal 615 
logistic model to the test dataset (30% of the TCGA samples). (F) Heatmap showing 616 
!27 
scaled methylation values of the 17-probe signature in the test dataset (30% of the TCGA 617 
samples). The bar plot on the left side shows the final coefficients for each probe in the 618 
model, and the bar plot on top shows the logistic probability generated by for each 619 
sample (Green: normal samples, magenta: cancer samples). 620 
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